<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661687</url>
  </required_header>
  <id_info>
    <org_study_id>544</org_study_id>
    <nct_id>NCT00661687</nct_id>
  </id_info>
  <brief_title>Comparative Performance of PureVision Lens Designs</brief_title>
  <official_title>A Study to Evaluate the Product Performance of the Redesigned Bausch &amp; Lomb PureVision® Contact Lens (Test) Compared to the Currently Marketed Bausch &amp; Lomb PureVision® Contact Lens (Control) When Worn on an Extended Wear Basis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the performance of the PureVision Lens designs
      when worn on a 30-day continuous wear basis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Responses to Symptoms/Complaints</measure>
    <time_frame>Measured at screening/dispensing visit, 1 day, 1 week and 1 month follow-up visits</time_frame>
    <description>Subjective responses to symptoms/complaints on a scale 0-100, where 100 is the most favorable score. Subjects rated various aspects of lens comfort, vision, and handling. The average of each symptom/complaint over all follow-up visits was assessed as the primary endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LogMAR Visual Acuity</measure>
    <time_frame>Mean over all visits - 1 day, 1 week, 1 month</time_frame>
    <description>The mean distance high contrast LogMAR visual acuity (VA) score for test eyes over all visits, determined by the total number of letters correctly identified on the logMAR chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lens Characteristics</measure>
    <time_frame>Over all scheduled visits day 1 - 1 month</time_frame>
    <description>Investigators evaluated study lenses, while on eye, for the number of eyes showing 100% wettability, no discoloration, none-light deposits, fully centered centration, and adequate movement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Purevision Contact Lens #1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PureVision Soft Contact Lens Design (currently marketed)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PureVision Contact Lens #2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Redesign of the currently marketed PureVision soft contact lens.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Currently Marketed PureVision Contact Lens.</intervention_name>
    <description>Contact lens for continuous wear</description>
    <arm_group_label>Purevision Contact Lens #1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alternate Design of the PureVision Contact Lens.</intervention_name>
    <description>Contact lens for continuous wear</description>
    <arm_group_label>PureVision Contact Lens #2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subject is myopic

          -  VA correctable to 0.3 logMAR or better (driving vision)

          -  Clear central cornea

        Exclusion Criteria:

          -  Systemic disease affecting ocular health

          -  using systemic or topical medications

          -  wear monovision, multifocal or toric contact lenses

          -  Any grade 2 or greater slit lamp findings
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Cairns, MCOptom, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benny Chian, MCOptom</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laser Focus Sdn Bhd, Vision Correction Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harvey Siy Uy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asian Eye Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser Focus Sdn Bhd, Vision Correction Centre</name>
      <address>
        <city>Johor Bahru</city>
        <zip>80400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asian Eye Institute</name>
      <address>
        <city>Makati City</city>
        <zip>1200</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <results_first_submitted>February 20, 2009</results_first_submitted>
  <results_first_submitted_qc>September 27, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2010</results_first_posted>
  <last_update_submitted>December 7, 2011</last_update_submitted>
  <last_update_submitted_qc>December 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began on 12/24/07 and lasted for 1 month. Participants were recruited from 10 Asian Sites.</recruitment_details>
      <pre_assignment_details>206 participants were enrolled. 204 participants were eligible and 189 completed the study. Study was a contralateral design with one eye of each patient randomly assigned to the experimental group and fellow eye to the control group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PureVision Contact Lens</title>
          <description>PureVision Contact Lens, Original Design and Alternate Design. Subjects randomly assigned to receive the Purevision test lens in one eye and the marketed Purevision lens in the fellow eye.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204">Contralateral study design, numbers indicate number of subjects.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189">Number indicates number of subjects successfully completing study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study related symptoms and complaints</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Positive slit lamp findings</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inability to maintain wearing schedule</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PureVision Contact Lens</title>
          <description>PureVision Contact Lens Original Design and New Design.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Mean and standard deviation measured on the eligible population of 204</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.1" spread="6.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Gender was measured in the eligible population of 204 participants (408 eyes).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Responses to Symptoms/Complaints</title>
        <description>Subjective responses to symptoms/complaints on a scale 0-100, where 100 is the most favorable score. Subjects rated various aspects of lens comfort, vision, and handling. The average of each symptom/complaint over all follow-up visits was assessed as the primary endpoint.</description>
        <time_frame>Measured at screening/dispensing visit, 1 day, 1 week and 1 month follow-up visits</time_frame>
        <population>All eligible participants</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision Contact Lens Design #1</title>
            <description>PureVision soft contact lens (currently marketed).</description>
          </group>
          <group group_id="O2">
            <title>PureVision Contact Lens Design #2</title>
            <description>Redesign of the currently marketed PureVision soft contact lens.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Responses to Symptoms/Complaints</title>
          <description>Subjective responses to symptoms/complaints on a scale 0-100, where 100 is the most favorable score. Subjects rated various aspects of lens comfort, vision, and handling. The average of each symptom/complaint over all follow-up visits was assessed as the primary endpoint.</description>
          <population>All eligible participants</population>
          <units>Visual Analogue Scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="15.07"/>
                    <measurement group_id="O2" value="81.2" spread="14.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LogMAR Visual Acuity</title>
        <description>The mean distance high contrast LogMAR visual acuity (VA) score for test eyes over all visits, determined by the total number of letters correctly identified on the logMAR chart.</description>
        <time_frame>Mean over all visits - 1 day, 1 week, 1 month</time_frame>
        <population>All Eligible, Dispensed Eyes</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision Contact Lens Design #1</title>
            <description>PureVision soft contact lens (currently marketed).</description>
          </group>
          <group group_id="O2">
            <title>PureVision Contact Lens Design #2</title>
            <description>Redesign of the currently marketed PureVision soft contact lens.</description>
          </group>
        </group_list>
        <measure>
          <title>LogMAR Visual Acuity</title>
          <description>The mean distance high contrast LogMAR visual acuity (VA) score for test eyes over all visits, determined by the total number of letters correctly identified on the logMAR chart.</description>
          <population>All Eligible, Dispensed Eyes</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.0678"/>
                    <measurement group_id="O2" value="0.003" spread="0.0673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lens Characteristics</title>
        <description>Investigators evaluated study lenses, while on eye, for the number of eyes showing 100% wettability, no discoloration, none-light deposits, fully centered centration, and adequate movement.</description>
        <time_frame>Over all scheduled visits day 1 - 1 month</time_frame>
        <population>Over All Scheduled Visits, All Eligible, Dispensed Eyes</population>
        <group_list>
          <group group_id="O1">
            <title>PureVision Contact Lens Design #1</title>
            <description>PureVision soft contact lens (currently marketed).</description>
          </group>
          <group group_id="O2">
            <title>PureVision Contact Lens Design #2</title>
            <description>Redesign of the currently marketed PureVision soft contact lens.</description>
          </group>
        </group_list>
        <measure>
          <title>Lens Characteristics</title>
          <description>Investigators evaluated study lenses, while on eye, for the number of eyes showing 100% wettability, no discoloration, none-light deposits, fully centered centration, and adequate movement.</description>
          <population>Over All Scheduled Visits, All Eligible, Dispensed Eyes</population>
          <units>Eyes</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lens wettability - 100% of anterior surface</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens discoloration - absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suboptimal lens deposits (medium/heavy) - absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens centration - excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lens movement - adequate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PureVision Contact Lens Design #1</title>
          <description>PureVision Contact Lens, Original Design. Subjects randomly assigned to receive the Purevision test lens in one eye and the marketed Purevision lens in the fellow eye.</description>
        </group>
        <group group_id="E2">
          <title>PureVision Contact Lens Design #2</title>
          <description>PureVision Contact Lens Test Design. Subjects randomly assigned to receive the Purevision test lens in one eye and the marketed Purevision lens in the fellow eye</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="204"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>2 participants discontinued due to adverse events, not classified as serious. One subject in the test group developed corneal ulcer, one subject in the control group developed a central epithelial defect, both conditions resolved following treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gerard Cairns</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>(585)338 - 5170</phone>
      <email>gerard.cairns@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

